America’s public health institutions made mistakes during the pandemic, but that does not justify the Trump administration’s ...

Chancellor Friedrich Merz’s trip to London on Thursday is the latest sign of a new world order, in which European nations are ...

Presented by AstraZeneca{beacon} Health Care Health Care   The Big Story CMS targets hospitals with site-neutral drug ruleThe ...

Anselamimab, which AstraZeneca acquired via Caelum Biosciences, missed its primary goal in two late-stage trials, but appeared to have some benefit in a subgroup of patients.

With the aim of being the largest life sector by 2035 behind only the US and China, the UK government is ramping up ...

ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.

Britain launched a life sciences sector plan on Wednesday to a mixed response from the pharmaceutical industry, which welcomed proposals to boost R&D but warned it would fail to keep firms competitive ...

An experimental AstraZeneca (NASDAQ:AZN) drug, anselamimab, failed to extend survival or cut heart-related hospitalizations in patients with a rare plasma cell disorder, disappointing hopes it could ...

AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare ...

True transformation requires AI that links customer data, knowledge bases, and operational systems to enable intelligent ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...

PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.